journal
MENU ▼
Read by QxMD icon Read
search

Quarterly Journal of Nuclear Medicine and Molecular Imaging

journal
https://www.readbyqxmd.com/read/28358186/evaluation-of-2-diuretic-18fluorine-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-imaging-protocols-for-intra-pelvic-cancer
#1
Lawrence O Dierickx, Laurent Dercle, Leonor Chaltiel, Olivier Caselles, Séverine Brillouet, Slimane Zerdoud, Frédéric Courbon
BACKGROUND: 18F-Fluorodeoxyglucose (FDG) PET/CT plays an important part in the oncological evaluation of the abdomen and pelvis, but the interpretation and quantification is often hampered by intense physiological urinary activity. We evaluate 2 different diuretic imaging protocols by comparing intensity of urinary activity and we look at the impact of multiple variables on the final urinary activity. METHODS: Comparative analysis of 102 patients (median age: 64) having intra-pelvic carcinoma...
March 29, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28299921/physical-training-improves-myocardial-perfusion-but-not-left-ventricular-function-response-to-exercise-in-patients-with-microvascular-angina
#2
Eduardo E Carvalho, Júlio C Crescêncio, Giovani L Santi, Luciano F Oliveira, Pedro V Schwartzmann, Lourenço Gallo, José A Marin-Neto, Marcus V Simões
BACKGROUND: Patients with primary microvascular angina (PMA) commonly exhibit abnormal left ventricular function (LVF) during exercise, potentially owing to myocardial ischemia. Herein, we investigated n PMA patients the effect of the reduction of myocardial perfusion disorders, by using aerobic physical training, upon LVF response to exercise. METHODS: Overall, 15 patients (mean age, 53.7±8.9 years) with PMA and 15 healthy controls (mean age, 51.0±9.4 years) were studied...
March 16, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28347132/radiolabeled-peptides-current-and-new-perspectives
#3
REVIEW
Marta Opalinska, Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak
Radiolabeled peptides have been the subject of research for over 20 years and during that time possibility/variety of peptide receptor imaging and later targeted radiotherapy increased significantly. The targeted receptors belong to the large family of G-protein-coupled receptors or tyrosine kinases receptors partially connected with them. They both regulate large signaling networks, control multiple cell functions and are implicated in many diseases including cancers. The essential feature of peptides used in nuclear medicine involves their ability to binding with high affinity and specify to their receptors overexpressed on tumor cells...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28347131/preclinical-in-vivo-cancer-straightway-to-patients
#4
REVIEW
Marion de Jong, Stephen Mather, Theodosia Maina
Detection of useful cellular targets has strongly stimulated personalized tumor-targeted imaging and therapy approaches, also involving synthesis and evaluation of nuclear imaging probes with potential for clinical applications. Reviews of preclinical and translational studies concerning such probes, including radiolabeled antibodies, nanobodies, affibodies, peptides, small molecule inhibitors, and nanoparticles, are presented in this issue. As most tracers described in these articles have been developed for the field of cancer imaging and radionuclide therapy, the current article on preclinical studies will focus on cancer research as well...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28347130/new-tracers-to-the-clinic
#5
Marion de Jong
No abstract text is available yet for this article.
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28217987/radiolabeled-prostate-specific-membrane-antigen-small-molecule-inhibitors
#6
REVIEW
Leon Will, Ida Sonni, Klaus Kopka, Clemens Kratochwil, Frederik L Giesel, Uwe Haberkorn
Prostate cancer (PC) is one of the most common malignancies worldwide. Prostate-specific membrane antigen (PSMA) has been found to be expressed in most PCs and represents an ideal target for diagnostic and therapeutic purposes. Numerous PSMA tracers have been recently developed. This review aims to provide an overview on the clinical influence of PSMA tracers in primary staging, biochemical recurrence (BCR) of PC and advanced, metastatic PC. Additionally, the use of PSMA tracers in systemic radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC), as well as non-prostatic specific uptake of PSMA tracers and the use of PSMA imaging to manage therapy have been described...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28124549/radiolabeled-inorganic-nanoparticles-for-positron-emission-tomography-imaging-of-cancer-an-overview
#7
REVIEW
Rubel Chakravarty, Shreya Goel, Ashutosh Dash, Weibo Cai
Over the last few years, a plethora of radiolabeled inorganic nanoparticles have been developed and evaluated for their potential use as probes in positron emission tomography (PET) imaging of a wide variety of cancers. Inorganic nanoparticles represent an emerging paradigm in molecular imaging probe design, allowing the incorporation of various imaging modalities, targeting ligands, and therapeutic payloads into a single vector. A major challenge in this endeavor is to develop disease-specific nanoparticles with facile and robust radiolabeling strategies...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28124548/european-regulations-for-the-introduction-of-novel-radiopharmaceuticals-in-the-clinical-setting
#8
Clemens Decristoforo, Ivan Penuelas, Marianne Patt, Sergio Todde
The development of novel radiopharmaceuticals is very rapid and highly innovative both for diagnostic and therapeutic applications. The translation into the clinic, however, is hampered by the high regulatory demands in Europe. This article describes the main rules, guidelines and guidance documents in the European Union in relation to the pharmaceutical regulatory framework. Until today a great number of radiopharmaceuticals are introduced clinically using specific national pathways outside the clinical trial regulation and examples are provided...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/26883515/clinical-application-of-fdg-pet-ct-in-metastatic-infections
#9
REVIEW
Ilse J Kouijzer, Fidel J Vos, Chantal P Bleeker-Rovers, Wim J Oyen
FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/26576734/therapeutic-schemes-in-177lu-and-90y-prrt-radiobiological-considerations
#10
Anna Sarnelli, Francesco Guerriero, Francesca Botta, Mahila Ferrari, Lidia Strigari, Lisa Bodei, Vincenzo D'Errico, Elisa Grassi, Federica Fioroni, Giovanni Paganelli, Roberto Orecchia, Marta Cremonesi
BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity. METHODS: Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data for the radiobiological model...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/25501326/staging-of-locally-advanced-breast-cancer-and-the-prediction-of-response-to-neoadjuvant-chemotherapy-complementary-role-of-scintimammography-and-18f-fdg-pet-ct
#11
Laura Evangelista, Anna R Cervino, Silvia Michieletto, Tania Saibene, Enrico Orvieto, Fernando Bozza, Cristina Ghiotto
BACKGROUND: The primary endpoint of the study was to established the role of sestamibi scintimammography and PET/CT findings in locally advanced breast cancer (LABC) before neoadjuvant systemic therapy (NST) in different histological subtypes. The secondary endpoint was to determine the role of FDG PET/CT as multi-drug resistance marker. METHODS: From January 2012, we prospectively enrolled 51 consecutive women (median age: 49 years; range: 27-76 yrs) with a biopsy-proven LABC...
June 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27982544/cardiovascular-preclinical-imaging
#12
REVIEW
Stephan G Nekolla, Christoph Rischpler, Anna Paschali, Constantinos Anagnostopoulos
Non-invasive imaging in the form of single-photon emission-computed tomography (SPECT), positron-emission tomography (PET), computed tomography (CT), echocardiography or magnetic resonance imaging (MRI) is a very useful tool for cardiovascular research as it allows assessment of biological processes in vivo. Nuclear imaging with SPECT and PET offers the advantage of high sensitivity, the potential for serial imaging, and reliable quantification. Currently a wide range of established as well as innovative agents is available and can be imaged with dedicated preclinical and clinical SPECT and PET imaging systems...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27982543/in-vivo-bioluminescence-imaging-using-orthotopic-xenografts-towards-patient-s-derived-xenograft-medulloblastoma-models
#13
Fatemeh Asadzadeh, Veronica Ferrucci, Pasqualino DE Antonellis, Massimo Zollo
BACKGROUND: Medulloblastoma is a cerebellar neoplasia of the central nervous system. Four molecular subgrups have been identified (MBWNT, MBSHH, MBgroup3 and MBgroup4) with distinct genetics and clinical outcome. Among these, MBgroup3-4 are highly metastatic with the worst prognosis. The current standard therapy includes surgery, radiation and chemotherapy. Thus, specific treatments adapted to cure those different molecular subgroups are needed. The use of orthotopic xenograft models, together with the non-invasive in vivo biolumiscence imaging (BLI) technology, is emerging during preclinical studies to test novel therapeutics for medulloblastoma treatment...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27858408/preclinical-imaging-in-oncology-advances-and-perspectives
#14
REVIEW
Francesca Iommelli, Viviana DE Rosa, Cristina Terlizzi, Silvana Del Vecchio
Preclinical imaging with radiolabeled probes became an integral part of the complex translational process that moves a newly developed compound from laboratory to clinical application. Imaging studies in animal tumor models may be undertaken to test a newly synthesized tracer, a newly developed drug or to interrogate, in the living organism, specific molecular and biological processes underlying tumor growth and progression. The aim of the present review is to outline the current knowledge and future perspectives of preclinical imaging in oncology by providing examples from recent literature...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27858407/preclinical-imaging-anesthesia-in-rodents
#15
REVIEW
Giancarlo Vesce, Fabiana Micieli, Ludovica Chiavaccini
Despite the outstanding progress achieved by preclinical imaging science, laboratory animal anesthesia remains quite stationary. Ninety percent of preclinical imaging studies are carried on small rodents (mice and rats) anesthetized by outdated injectable and/or inhalation agents. A need for imaging awake (conscious) animals is questionably registered mainly for brain research, for phMRI and for accomplishing pain and analgesia studies. A need for improving current rodent anesthesia protocols and for enforcing the 3Rs paradigm is sought...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27858406/molecular-imaging-of-neuroinflammation-in-preclinical-rodent-models-using-positron-emission-tomography
#16
REVIEW
Sara Gargiulo, Anna R Coda, Mariarosaria Panico, Matteo Gramanzini, Rosa M Moresco, Sylvie Chalon, Sabina Pappatà
Neuroinflammation (NI) is an adaptive response to different noxious stimuli, involving microglia, astrocytes and peripheral immune cells. NI is a hallmark of several acute and chronic diseases of central nervous system (CNS) and contributes to both damage and repair of CNS tissue. Interventional or genetically modified rodent models mimicking human neuropathologies may provide valuable insights on basic mechanisms of NI, but also for improving the development of new diagnostic and therapeutic strategies. Preclinical positron emission tomography (PET) allows to investigate noninvasively the inflammatory response in CNS of rodent models at a molecular level, validating innovative probes for early diagnosis, and characterizing the time course of neuroinflammatory changes and their relationship with disease progression, as well as the effects of experimental treatments with high translational potential...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27858405/advances-in-molecular-preclinical-therapy-mediated-by-imaging
#17
REVIEW
Adelaide Greco, Sandra Albanese, Luigi Auletta, Flavia DE Carlo, Marco Salvatore, Candace M Howard, Pier P Claudio
Several advances have been made toward understanding the biology of cancer and most of them are due to robust genetic studies that led to the scientific recognition that although many patients have the same type of cancer their tumors may have harbored different molecular alterations. Personalized therapy and the development of advanced techniques of preclinical imaging and new murine models of disease are emerging concepts that are allowing mapping of disease markers in vivo and in some cases also receptor targeted therapy...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27858404/advances-in-multimodal-molecular-imaging
#18
REVIEW
Luigi Auletta, Matteo Gramanzini, Sara Gargiulo, Sandra Albanese, Marco Salvatore, Adelaide Greco
Preclinical molecular imaging is an emerging field. Improving the ability of scientists to study the molecular basis of human pathology in animals is of the utmost importance for future advances in all fields of human medicine. Moreover, the possibility of developing new imaging techniques or of implementing old ones adapted to the clinic is a significant area. Cardiology, neurology, immunology and oncology have all been studied with preclinical molecular imaging. The functional techniques of photoacoustic imaging (PAI), fluorescence molecular tomography (FMT), positron emission tomography (PET), and single photon emission computed tomography (SPECT) in association with each other or with the anatomic reference provided by computed tomography (CT) as well as with anatomic and functional information provided by magnetic resonance (MR) have all been proficiently applied to animal models of human disease...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/25479418/the-impact-of-different-18fdg-pet-healthy-subject-scans-for-comparison-with-single-patient-in-spm-analysis
#19
COMPARATIVE STUDY
Francesca Gallivanone, Pasquale A Della Rosa, Daniela Perani, Maria C Gilardi, Isabella Castiglioni
BACKGROUND: Statistical Parametric Mapping (SPM) has been applied for single-subject evaluation of [18F]FDG uptake in Alzheimer Disease (AD). In a single-subject framework, the patient is compared to a dataset of [18F]FDG PET images from healthy subjects (HS) evaluating brain metabolic abnormalities. No studies exist that assess the effects on SPM analysis of HS [18F]FDG PET datasets acquired from different subjects and using different PET scanners including the same or different PET scanners than those used for patients...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/25289633/stable-metabolic-disease-on-fdg-pet-provides-information-on-response-to-endocrine-therapy-for-breast-cancer
#20
Vibeke Kruse, Christophe VAN DE Wiele, Alex Maes, Marleen Borms, Hans Pottel, Simon VAN Belle, Veronique Cocquyt
BACKGROUND: The aim of this study was to assess whether outcome in advanced breast cancer patients is related to metabolic response to endocrine therapy determined by fluorodeoxyglucose positron-emission tomography (FDG-PET). METHODS: We retrospectively identified 21 consecutive breast cancer patients receiving endocrine therapy for metastatic disease (mean number of previous therapies 3.6±3.5). All patients had been evaluated with at least 2 FDG-PETs. The first scan was performed by initiation of endocrine therapy...
March 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
journal
journal
40679
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"